- The FDA approves Sun Pharmaceutical Industries' (OTCPK:SMPQY) YONSA (abiraterone acetate), combined with methylprednisolone, for the treatment of patients with metastatic castration-resistant prostate cancer.
- Licensor Churchill Pharmaceuticals, LLC will be eligible for an upfront payment, sales milestones and royalties.
FDA OKs Sun Pharma's Yonsa for advanced prostate cancer
Recommended For You
More Trending News
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| SMPQY | - | - |
| Sun Pharmaceuticals Industries Ltd. ADR | ||